Yeh but based on previously approved MAB AD therapies the hoped for revenue is tiny compared to what had been hoped for since no public healthcare systems here or abroad are paying for it.
The amount of people to pay out of pocket for a dangerous and minimally effective treatment is too small for the serious revenue a BP needs to affect their bottom line.
Market Data 
Markets 
AI
